Novolimus-eluting coronary stent - Elixir Medical

Drug Profile

Novolimus-eluting coronary stent - Elixir Medical

Alternative Names: DESolve bioresorbable novolimus eluting coronary stent system; DESolve novolimus eluting coronary stent system; DESolve Novolimus Eluting Coronary Stent System; DESolve® NXT Novolimus Eluting Bioresorbable Coronary Scaffold System; DESyne BD novolimus eluting coronary stent system; DESyne BD Novolimus Eluting Coronary Stent System; DESyne Biodegradable novolimus eluting coronary stent system; DESyne novolimus eluting coronary stent system; DESyne Novolimus Eluting Coronary Stent System; DESyne® Nx Novolimus Eluting Coronary Stent System; Elixir DESyne Coronary Stent System; Excella Novolimus™-Eluting Coronary Stent System; Novolimus-eluting stent

Latest Information Update: 04 Nov 2016

Price : $50

At a glance

  • Originator Elixir Medical Corporation
  • Class Cardiovascular therapies; Macrolides
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary artery restenosis

Most Recent Events

  • 01 Nov 2016 Positive initial 6-month efficacy data from the DESolve™ Cx clinical trial in Coronary artery restenosis (Prevention) released by Elixir Medical
  • 15 Oct 2015 Efficacy data from the DESolve® Nx trial in Coronary artery restenosis (prevention) released by Elixir Medical
  • 03 Mar 2015 Phase III development is ongoing for Coronary artery restenosis (Prevention) in Australia, Brazil and New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top